Sandoz Canada has marked its entry into oncology biosimilars by launching Ziextenzo (pegfilgrastim) and Riximyo (rituximab), on the back of securing Health Canada approvals earlier this year and reaching a negotiated agreement with the Pan-Canadian Pharmaceutical Alliance.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?